Clinical Trials Logo

Acquired Immune Deficiency Syndrome clinical trials

View clinical trials related to Acquired Immune Deficiency Syndrome.

Filter by:

NCT ID: NCT02670772 Completed - Clinical trials for Human Immunodeficiency Virus

Dose Optimisation of Stavudine for the Treatment of HIV Infection

D4T
Start date: July 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate whether low dose stavudine (d4T) is non-inferior (in terms of both viral suppression and toxicity) to tenofovir (TDF) after 2 years of HIV treatment.

NCT ID: NCT01741844 Completed - Clinical trials for Acquired Immune Deficiency Syndrome

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

Start date: September 2012
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess the safety data of etravirine in a natural clinical practice.

NCT ID: NCT01741831 Completed - Clinical trials for Acquired Immune Deficiency Syndrome

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

Start date: July 2012
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess the safety data of darunavir in a natural clinical practice.

NCT ID: NCT01173510 Withdrawn - HIV Infections Clinical Trials

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

Start date: August 23, 2010
Phase: Phase 4
Study type: Interventional

Human Immunodeficiency Virus (HIV) infection is permanently established by integrating a deoxyribonucleic acid (DNA) copy into the human chromosome, a step also necessary to complete the Human Immunodeficiency Virus (HIV)replication cycle. Standard treatment of HIV infection suppresses Human Immunodeficiency Virus (HIV)replication and has not been able to eliminate Human Immunodeficiency Virus (HIV)from an infected person because of the integrated Human Immunodeficiency Virus (HIV). Raltegravir (RAL), the first approved antiretroviral (ARV) in a new class called integrase inhibitors, works by preventing integration of Human Immunodeficiency Virus (HIV). For participants with Human Immunodeficiency Virus (HIV)who have never taken antiretroviral medications, this research study will test whether Raltegravir (RAL), a recommended first-line ARV, can eliminate Human Immunodeficiency Virus (HIV)from key immune system cells.

NCT ID: NCT00972699 Completed - Tuberculosis Clinical Trials

Mentor Mothers: A Sustainable Family Intervention in South African Townships

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test a mother-to-mother intervention during pregnancy and after delivery with Mothers Living with HIV (MLH)in South Africa. We hypothesize that the intervention will enhance the adjustment of the children of MLH by improving the health and mental health of MLH which benefits their children, as well as the MLH.

NCT ID: NCT00872417 Not yet recruiting - HIV Infections Clinical Trials

Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients

Start date: March 2009
Phase: Phase 4
Study type: Interventional

This study will recruit 520 treatment-naive and 150 treatment-experienced patients to take the first line or second line of antiviral therapy. This study aims to set up a well-trained clinical and laboratory team in China, to explore the effects and side-effects of the first-line and the second line of ARV treatment in Chinese HIV/AIDS adult patients, to investigate the side-effects of ARV drugs, such as hepatotoxicity, lipoatrophy, cardiovascular influence, to explore the pharmacokinetics/pharmacodynamics (PK/PD) of Chinese generic ARV regiments and effective drug concentrations and to explore primary and secondary drug resistance in China and the immune reconstitution characters of long term ARV in Chinese adult AIDS patients. This study might provide more practical and optimizing prove for the treatment guideline for resource limited areas.

NCT ID: NCT00814879 Completed - HIV Infections Clinical Trials

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Start date: May 2009
Phase: N/A
Study type: Interventional

This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.

NCT ID: NCT00775606 Terminated - Clinical trials for Acquired Immune Deficiency Syndrome

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Start date: October 2008
Phase: Phase 4
Study type: Interventional

The ideal anti-HIV medications for patients with advanced HIV disease is unknown. There is evidence that anti-HIV regimens that contain protease inhibitors can enhance immune function better than regimens that do not contain protease inhibitors. This is a study that will determine the difference in immune enhancement capabilities between an anti-HIV regimen that contains the protease inhibitor - lopinavir-ritonavir, and a regimen that contains efavirenz. Both medications are recommended as first line treatments for HIV-infected patients. This study will recruit HIV-positive patients that need to start anti-HIV treatment because their CD4+ T-cells are below 200. The usual threshold for starting treatment is a CD4+ T-cell less than 350. Subjects will be randomized to treatment with either an anti-HIV regimen that contains lopinavir-ritonavir or a regimen that contains efavirenz. The study will determine the difference in immune reconstitution over 24 weeks of treatment with study medications. Among the immune parameters that will be measured is the ability of each subject to respond to vaccination with the tetanus-diphtheria vaccine and the 23-valent pneumococcal vaccine. Both vaccines are also recommended for HIV-positive patients but HIV-positive patients tend to have a lower response rate to these vaccines.

NCT ID: NCT00758212 Enrolling by invitation - HIV Infections Clinical Trials

Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem

Start date: November 2008
Phase: N/A
Study type: Interventional

Influenza vaccination has proved it's effectiveness over many years of usage including HIV/AIDS patients who are immunocompromised. In those patients, however, a noted rise in HIV viral load which follows intramuscular injection of the vaccine is of unknown significance over the long run. Mesotherapy is a procedure developed and practiced in france by which a reduced and diluted amounts of antigens is being introduced by multiple intradermal injections over the torso and upper back. Mesotherapy is mainly used as a vehicle for introducing pain medicine and cosmetics.

NCT ID: NCT00637962 Terminated - HIV Infections Clinical Trials

Reactogenicity and Immunogenicity of Vaginal CNgp140

SG06RS02
Start date: September 2007
Phase: Phase 1
Study type: Interventional

To determine the local (cervico-vaginal) and systemic (whole body) safety of vaginal immunisation with CN54gp140 glycoprotein administered 9 times over a 3 week period.